Previous history of Hodgkin or mediastinal non-Hodgkin lymphoma treated with mediastinal radiotherapy with or without anthracycline-containing chemotherapy
Conditions
Interventions
None
Sponsors
Department of radiotherapy and cardiology of Erasmus MC
Eligibility
Inclusion criteria
Inclusion criteria: • Previous history of Hodgkin or mediastinal non-Hodgkin lymphoma treated with mediastinal radiotherapy with or without anthracycline-containing chemotherapy • Planned visit at the BETER clinic • Written informed consent • Age >= 18 years • A minimum of 5 years of disease free survival
Exclusion criteria
Exclusion criteria: • Not currently under treatment for malignant disease (unless basal cell carcinoma). • Patients who already underwent a surgical intervention for cardiac problems, such as heart valve replacement or a coronary artery bypass grafting (CABG).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective is to evaluate in terms of sensitivity, specificity and predictive value a panel of cardiac biomarkers for the early detection of an increase in cardiac symptoms for HL and (selected) NHL long-term survivors. The panel of biomarkers will be compared to an evaluation including clinical assessment, ECG, heart US and PROMs. | — |
Secondary
| Measure | Time frame |
|---|---|
| – To describe the early symptoms of long-term cardiac toxicity induced by radiotherapy with or without chemotherapy for HL and NHL patients. – Develop a screening tool for the early detection of cardiac toxicity including biomarkers, imaging tests and PROMs. – Difference in score of the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) and the Seattle Angina Questionnaire (SAQ-7). – To evaluate the value of cardiac MRI as an objective diagnostic tool for mediastinal radiotherapy and/or chemotherapy induced cardiac toxicities. – To evaluate the dose effect relationship between the detected increase in cardiac symptoms and various late severe cardiac toxicities. - Evaluation of the radiation with/without anthracycline dose effect relationship, and the impact of other factors of risk (age at treatment, gender, body mass index (BMI), hypertension, diabetes, dyslipidaemia, and tobacco use). | — |
Contacts
Public ContactOlivier Manintveld
Erasmus MC
Outcome results
None listed